| PRECLINICAL | evidence | The First Triple Agonist for Antiobesity: Retatrutide. | Retatrutide | — | 2024-10-08 |
| PRECLINICAL | evidence | Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. | Retatrutide | — | 2024-10-03 |
| PRECLINICAL | evidence | Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? | Retatrutide | Weight & fat loss | 2024-10-01 |
| PRECLINICAL | evidence | The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases. | Retatrutide | Lipid & cardiovascular markers | 2024-10-01 |
| PRECLINICAL | evidence | Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care. | Retatrutide | — | 2024-09-07 |
| PRECLINICAL | evidence | Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. | Retatrutide | Weight & fat loss | 2024-09-01 |
| PRECLINICAL | evidence | Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. | Retatrutide | — | 2024-09-01 |
| PRECLINICAL | evidence | Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity. | Retatrutide | Weight & fat loss | 2024-08-01 |
| PRECLINICAL | evidence | Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy. | Retatrutide | Weight & fat loss | 2024-07-27 |
| PRECLINICAL | evidence | Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. | Retatrutide | — | 2024-07-17 |
| PRECLINICAL | evidence | Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials. | Retatrutide | Glycemic control | 2024-07-01 |
| PRECLINICAL | evidence | Gut hormones and appetite regulation. | Retatrutide | — | 2024-06-01 |
| PRECLINICAL | evidence | Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review. | Retatrutide | Weight & fat loss | 2024-06-01 |
| PRECLINICAL | evidence | A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. | Retatrutide | Weight & fat loss | 2024-05-01 |
| PRECLINICAL | evidence | Advancements in the management of obesity: a review of current evidence and emerging therapies. | Retatrutide | Weight & fat loss | 2024-05-01 |
| PRECLINICAL | evidence | Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? | Retatrutide | Glycemic control | 2024-05-01 |
| PRECLINICAL | evidence | Top studies of 2023 relevant to primary care: From the PEER team. | Retatrutide | — | 2024-04-01 |
| PRECLINICAL | evidence | Rare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies. | Retatrutide | Weight & fat loss | 2024-04-01 |
| PRECLINICAL | evidence | An overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update. | Retatrutide | Weight & fat loss | 2024-04-01 |
| PRECLINICAL | evidence | Recent advances in peptide-based therapies for obesity and type 2 diabetes. | Retatrutide | — | 2024-03-01 |
| PRECLINICAL | evidence | Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies. | Retatrutide | Glycemic control | 2024-03-01 |
| PRECLINICAL | evidence | Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks. | Retatrutide | Weight & fat loss | 2024-02-01 |
| PRECLINICAL | evidence | Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play? | Retatrutide | Glycemic control | 2024-02-01 |
| PRECLINICAL | evidence | Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. | LY3437943 | — | 2024-02-01 |
| PRECLINICAL | evidence | The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. | Retatrutide | Weight & fat loss | 2024-02-01 |
| PRECLINICAL | evidence | Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond. | Retatrutide | Weight & fat loss | 2024-02-01 |
| PRECLINICAL | evidence | At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide. | Retatrutide | — | 2024-01-02 |
| PRECLINICAL | evidence | Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus? | Retatrutide | Glycemic control | 2024-01-01 |
| PRECLINICAL | evidence | Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. | Retatrutide | — | 2024-01-01 |
| PRECLINICAL | evidence | Retatrutide. | Retatrutide | — | 2024-01-01 |
| PRECLINICAL | evidence | Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity. | Retatrutide | Glycemic control | 2024-01-01 |
| PRECLINICAL | evidence | Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape? | Retatrutide | — | 2023-11-01 |
| PRECLINICAL | evidence | Triple-Hormone-Receptor Agonist Retatrutide for Obesity. | Retatrutide | Weight & fat loss | 2023-10-26 |
| PRECLINICAL | evidence | Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. | Retatrutide | Weight & fat loss | 2023-10-26 |
| PRECLINICAL | evidence | Triple-Hormone-Receptor Agonist Retatrutide for Obesity. | Retatrutide | Weight & fat loss | 2023-10-26 |
| PRECLINICAL | evidence | [From GLP1 receptor agonists to triple hormone receptor activation supplemented with glucagon receptor agonism.]. | Retatrutide | — | 2023-10-22 |
| PRECLINICAL | evidence | The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. | Retatrutide | Glycemic control | 2023-09-01 |
| PRECLINICAL | evidence | A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena. | Retatrutide | Glycemic control | 2023-08-12 |
| PRECLINICAL | evidence | Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss. | Retatrutide | Weight & fat loss | 2023-07-25 |
| PRECLINICAL | evidence | Retatrutide showing promise in obesity (and type 2 diabetes). | LY3437943 | — | 2023-07-01 |
| PRECLINICAL | evidence | Retatrutide: a triple incretin receptor agonist for obesity management. | Retatrutide | — | 2023-07-01 |
| PRECLINICAL | evidence | Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943. | LY3437943 | — | 2023-06-16 |
| PRECLINICAL | evidence | Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? | LY3437943 | Glycemic control | 2023-05-01 |
| PRECLINICAL | evidence | Enteroendocrine cell regulation of the gut-brain axis. | Retatrutide | — | 2023-01-01 |
| PRECLINICAL | evidence | Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease. | Retatrutide | Glycemic control | 2023-01-01 |
| INDEPENDENT-REVIEW | review | I lost 46 lbs in 8 weeks with Retatrutide
Current weight as of this post: 187 lbs
Started at 2.0mg on May 23, 2026
Currently & sticking to 5.0mg, July 11, 2026
Keto diet, high protein, no carbs, no sugars
30 minutes of freestyle swimming 5 days a week.
Resistance training 5x a week, progressive overload. Compound movements focused.
Drank only spring water
Lots of electrolytes, | COMMUNITY | — | 2026-07-27 |
| INDEPENDENT-REVIEW | review | [28M] Transitioning Wegovy to Retatrutide and adding CJC+IPA (no DAC), and KLOW80: What blood tests should I run?
Hey everyone. I am a 28-year-old male living in Germany and I am planning a major update to my protocol. Before this I want to get a full complete, uncompromised tests and want to get advice from the community on what specific biomarkers and tests I should be requesting.
Currently, I | COMMUNITY | — | 2026-07-27 |
| INDEPENDENT-REVIEW | review | 2 Weeks into Retatrutide
[removed] | COMMUNITY | — | 2026-07-27 |
| INDEPENDENT-REVIEW | review | 2 Weeks Of Retatrutide (GLP-3R): Documenting My Journey With Third-Party Testing
[removed] | COMMUNITY | — | 2026-07-27 |
| INDEPENDENT-REVIEW | review | Mixed up my 10mg and 30mg Retatrutide vials. Any way to identify which is which before I reconstitute?
I accidentally mixed up five lyophilized retatrutide vials. Some are **10mg** and some are **30mg**, but they are completely unlabeled now.
I know this may not be possible, but I’m hoping someone with experience might notice something I don’t.
A few details:
They’re all from the same | COMMUNITY | — | 2026-07-27 |